Jaguar Animal Health (NASDAQ:JAGX) has submitted a formal request to the FDA’s Center for Veterinary Medicine for a determination whether Canalevia qualifies under the requirements of the Minor Use and Minor Species...

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company’s autologous cell therapy for the treatment of androgenetic alopecia (pattern...

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical...

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) plans to initiate a single Phase 3 clinical trial (Aurora), with a design consistent with that of the continuing Aura-LV clinical trial of voclosporin for the treatment of...

Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a...

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private...

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) Phase 2b AURA-LV study of voclosporin in lupus nephritis (LN) met its complete and partial remission (CR/PR) endpoints at 48 weeks. The study demonstrated statistically...

The CBS affiliate in Pittsburgh, KDKA-TV has produced a segment on the benefits of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine for the maintenance treatment of opioid addiction. Dr...

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has signed agreements with two European firms to get the company’s commercial-grade RCI-02 dermal injector prototypes manufactured and tested. “The...

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi...

The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company’s TeloView software platform. The purpose of Telo...

Arch Therapeutics (OTCQB:ARTH) priced a registered direct offering of 10,166,664 units, with each unit consisting of a common share and 0.55 of a Series F warrant, at a purchase price of 60 cents a unit for gross...

Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a...

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium...

Arch Therapeutics (OTCQB:ARTH) announced that the 510(k) filing for external use of the AC5 Topical Hemostatic device would be advanced to mid-2017 from the previously announced target of late 2017. “Our...

Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for...

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the...

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. The first patent has been validated in a total of 14 national...

YouScript, a clinical decision support tool designed to assist in medication therapy management, has been shown to reduce hospital readmissions by 52% and ER visits by 42% in patients over 50 taking multiple medications...

BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute. The technology was...